Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Survival impact of prolonged postoperative radiation therapy for patients with glioblastoma treated with combined-modality therapy.

Yusuf MB, Gaskins J, Amsbaugh MJ, Woo S, Burton E.

Neurooncol Pract. 2019 Mar;6(2):112-123. doi: 10.1093/nop/npy027. Epub 2018 Jul 20.

PMID:
31386043
2.

Survival Impact of Time to Initiation of Adjuvant Radiation for Merkel Cell Carcinoma: An Analysis of the National Cancer Database.

Yusuf M, Gaskins J, Tennant P, Bumpous J, Dunlap N.

Pract Radiat Oncol. 2019 Jul - Aug;9(4):e372-e385. doi: 10.1016/j.prro.2019.03.004. Epub 2019 Mar 26.

PMID:
30926480
3.

Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.

Niranjan A, Kano H, Iyer A, Kondziolka D, Flickinger JC, Lunsford LD.

J Neurosurg. 2015 Apr;122(4):757-65. doi: 10.3171/2014.11.JNS13295. Epub 2015 Jan 16.

PMID:
25594327
4.

Failure to complete standard radiation therapy in glioblastoma patients: Patterns from a national database with implications for survival and therapeutic decision making in older glioblastoma patients.

Burton E, Yusuf M, Gilbert MR, Gaskins J, Woo S.

J Geriatr Oncol. 2019 Sep 11. pii: S1879-4068(19)30208-5. doi: 10.1016/j.jgo.2019.08.014. [Epub ahead of print]

PMID:
31521589
5.

Concurrent chemoradiotherapy versus radiotherapy alone for "biopsy-only" glioblastoma multiforme.

Kole AJ, Park HS, Yeboa DN, Rutter CE, Corso CD, Aneja S, Lester-Coll NH, Mancini BR, Knisely JP, Yu JB.

Cancer. 2016 Aug 1;122(15):2364-70. doi: 10.1002/cncr.30063. Epub 2016 May 12.

6.

Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.

Jastaniyah N, Murtha A, Pervez N, Le D, Roa W, Patel S, Mackenzie M, Fulton D, Field C, Ghosh S, Fallone G, Abdulkarim B.

Radiat Oncol. 2013 Feb 20;8:38. doi: 10.1186/1748-717X-8-38.

7.

Timing of Adjuvant Radiotherapy in Glioblastoma Patients: A Single-Institution Experience With More Than 400 Patients.

Wang TJ, Jani A, Estrada JP, Ung TH, Chow DS, Soun JE, Saad S, Qureshi YH, Gartrell R, Isaacson SR, Cheng SK, McKhann GM 2nd, Bruce JN, Lassman AB, Sisti MB.

Neurosurgery. 2016 May;78(5):676-82. doi: 10.1227/NEU.0000000000001036.

PMID:
26440447
8.

Combined-Modality Therapy With Radiation and Chemotherapy for Elderly Patients With Glioblastoma in the Temozolomide Era: A National Cancer Database Analysis.

Rusthoven CG, Koshy M, Sher DJ, Ney DE, Gaspar LE, Jones BL, Karam SD, Amini A, Ormond DR, Youssef AS, Kavanagh BD.

JAMA Neurol. 2016 Jul 1;73(7):821-8. doi: 10.1001/jamaneurol.2016.0839.

PMID:
27214765
9.

Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience.

Ciammella P, Galeandro M, D'Abbiero N, Podgornii A, Pisanello A, Botti A, Cagni E, Iori M, Iotti C.

Clin Neurol Neurosurg. 2013 Sep;115(9):1609-14. doi: 10.1016/j.clineuro.2013.02.001. Epub 2013 Feb 26.

PMID:
23453151
10.

Prognostic factors in glioblastoma multiforme patients receiving high-dose particle radiotherapy or conventional radiotherapy.

Matsuda M, Yamamoto T, Ishikawa E, Nakai K, Zaboronok A, Takano S, Matsumura A.

Br J Radiol. 2011 Dec;84 Spec No 1:S54-60. doi: 10.1259/bjr/29022270. Epub 2011 Mar 22.

11.

The impact of adjuvant radiation therapy for high-grade gliomas by histology in the United States population.

Rusthoven CG, Carlson JA, Waxweiler TV, Dally MJ, BarĂ³n AE, Yeh N, Gaspar LE, Liu AK, Ney DE, Damek DM, Lillehei KO, Kavanagh BD.

Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):894-902. doi: 10.1016/j.ijrobp.2014.07.046. Epub 2014 Oct 18.

PMID:
25585784
12.

Adjuvant Radiation Therapy Treatment Time Impacts Overall Survival in Gastric Cancer.

McMillan MT, Ojerholm E, Roses RE, Plastaras JP, Metz JM, Mamtani R, Karakousis GC, Fraker DL, Drebin JA, Stripp D, Ben-Josef E, Datta J.

Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):326-36. doi: 10.1016/j.ijrobp.2015.05.025. Epub 2015 May 21.

PMID:
26232857
13.

Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).

Mallick S, Kunhiparambath H, Gupta S, Benson R, Sharma S, Laviraj MA, Upadhyay AD, Julka PK, Sharma D, Rath GK.

J Neurooncol. 2018 Oct;140(1):75-82. doi: 10.1007/s11060-018-2932-3. Epub 2018 Jun 23.

PMID:
29936695
14.

Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.

Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R.

J Clin Oncol. 2006 Jun 1;24(16):2563-9.

PMID:
16735709
15.

Patterns of Care and Outcomes of Hypofractionated Chemoradiation Versus Conventionally Fractionated Chemoradiation for Glioblastoma in the Elderly Population.

Haque W, Verma V, Butler EB, Teh BS.

Am J Clin Oncol. 2018 Feb;41(2):167-172. doi: 10.1097/COC.0000000000000417.

PMID:
29369825
16.

The impact of timing of adjuvant therapy on survival for patients with glioblastoma: An analysis of the National Cancer Database.

Amsbaugh MJ, Yusuf M, Gaskins J, Burton E, Woo S.

J Clin Neurosci. 2019 Aug;66:92-99. doi: 10.1016/j.jocn.2019.05.013. Epub 2019 May 16.

PMID:
31104962
17.

Patterns of care and predictors of adjuvant therapies in elderly patients with glioblastoma: An analysis of the National Cancer Data Base.

Amsbaugh MJ, Yusuf MB, Gaskins J, Burton EC, Woo SY.

Cancer. 2017 Sep 1;123(17):3277-3284. doi: 10.1002/cncr.30730. Epub 2017 Apr 27.

18.

Association of Adjuvant Chemoradiotherapy vs Radiotherapy Alone With Survival in Patients With Resected Major Salivary Gland Carcinoma: Data From the National Cancer Data Base.

Amini A, Waxweiler TV, Brower JV, Jones BL, McDermott JD, Raben D, Ghosh D, Bowles DW, Karam SD.

JAMA Otolaryngol Head Neck Surg. 2016 Nov 1;142(11):1100-1110. doi: 10.1001/jamaoto.2016.2168.

PMID:
27541166
19.

Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma.

Sun MZ, Oh T, Ivan ME, Clark AJ, Safaee M, Sayegh ET, Kaur G, Parsa AT, Bloch O.

J Neurosurg. 2015 May;122(5):1144-50. doi: 10.3171/2014.9.JNS14193. Epub 2015 Mar 13.

PMID:
25768833
20.

Newly diagnosed glioblastoma: adverse socioeconomic factors correlate with delay in radiotherapy initiation and worse overall survival.

Pollom EL, Fujimoto DK, Han SS, Harris JP, Tharin SA, Soltys SG.

J Radiat Res. 2018 Mar 1;59(suppl_1):i11-i18. doi: 10.1093/jrr/rrx103.

Supplemental Content

Support Center